Overview


Antiadrenergic agents act on adrenergic receptors and block the activity of catecholamines, primarily norepinephrine and epinephrine, on receptors sensitive to adrenergic compounds within the sympathetic nervous system. The sympathetic nervous system coordinates the body's "fight or flight" response in the body, which includes increasing heart rate, constricting blood vessels, and other physiological reactions that prepare the body to respond to stress or danger. By blocking the action of these neurotransmitters, antiadrenergic agents can have various effects on the body, such as reducing heart rate, lowering blood pressure, and relaxing blood vessels. These drugs commonly treat hypertension (high blood pressure), certain heart conditions, and anxiety.

There are two major types of adrenergic receptors–alpha and beta—and several subtypes within each category. Antiadrenergic drugs can be categorized based on their specificity for the different receptors. The major classes include selective alpha-1 receptor blockers, nonselective alpha-blockers, selective beta-1 receptor blockers, nonselective beta-blockers, and mixed alpha- and beta-blockers. Many beta receptors exist in the heart, so these drugs are primarily used for cardiac indications, including angina, MI, heart failure, and hypertension (as an alternative agent). Alpha receptors are prevalent in smooth muscle, especially within the vasculature. Alpha-blockers induce significant vasodilation and are prescribed for hypertension and BPH (benign prostatic hyperplasia). Significant adverse effects are possible.

FutureWise Market Research has published a report that provides an insightful analysis anti adrenergic agent market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti adrenergic agent market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • C.H. Boehringer Sohn
  • Teva
  • AstraZeneca
  • Pfizer
  • GlaxoSmithKline

(Note: The list of the major players will be updated with the latest market scenario and trends)

The growing prevalence of medication that influences noradrenergic activity holds promising implications addressing hypertension, expected to drive the growth of anti adrenergic agent market during the forecast period. When administered under psychiatric guidance, both antiadrenergic and adrenergic blocking drugs present opportunities for managing conditions spanning thought disorders, such as anxiety, mood change, and motor dysfunctions. These therapeutic agents exploit the complex interplay of adrenergic receptors, presenting a multidimensional approach to healthcare interventions. Furthermore, some anti-adrenergic agents, which carry adverse side effects such as hypotension, anxiety, bradycardia, and fatigue, are expected to impede the market growth. These side effects may also hinder the patient population. The possibility of hypotension may raise concern in individuals already struggling with low blood pressure or conditions susceptible to blood pressure fluctuations. Similarly, bradycardia-related drawbacks may deter usage in patients with pre-existing heart rhythm irregularities, and the propensity for fatigue could pose challenges for those already encountering fatigue-associated medical conditions, further hindering the growth of the anti-adrenergic agent market. Moreover, the alternative treatment options, encompassing innovative drug types and advanced medical devices, may shift focus and resources from traditional anti-adrenergic therapies. These novel approaches, driven by advances in medical science and technology, could offer new alternatives for addressing various health conditions, including those traditionally managed by anti-adrenergic agents. Therefore, this change towards more unique options might significantly hinder the growth of the anti-adrenergic agent market.

By Product Type

  • α-Blockers
  • β-Blockers

By End User Type

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest revenue share in the market in 2022. It is attributed to the high prevalence of COPD, asthma, and cardiac arrest cases in developed countries, well-established healthcare facilities, and favorable medical reimbursement policies. This region's leading share is evident. Furthermore, the demand for monitoring and assessing the competitive environment encompasses aspects such as new product introductions, mergers and acquisitions, and technological advancements. Therefore, the factors mentioned above are expected to drive the growth of the anti-adrenergic agent market during the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti Adrenergic Agent Market By Product Type, By End User Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anti Adrenergic Agent Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti Adrenergic Agent Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anti Adrenergic Agent Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anti Adrenergic Agent Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. α-Blockers
        2. β-Blockers

  • 8.   Anti Adrenergic Agent Market, By End User Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 9.   North America Anti Adrenergic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Anti Adrenergic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Anti Adrenergic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Anti Adrenergic Agent Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. C.H. Boehringer Sohn
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Teva
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Adrenergic Drugs Market

Read More

Alpha 2C Adrenergic Receptor Market

Read More
Partner

Our Clients